Deciphera Pharmaceuticals Inc
F:D05
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
10.575
42.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one D05 stock under the Base Case scenario is 13.51 EUR. Compared to the current market price of 42.4 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Deciphera Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for D05 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Deciphera Pharmaceuticals Inc
Balance Sheet Decomposition
Deciphera Pharmaceuticals Inc
Current Assets | 349.9m |
Cash & Short-Term Investments | 272.5m |
Receivables | 32.7m |
Other Current Assets | 44.7m |
Non-Current Assets | 71m |
Long-Term Investments | 26.8m |
PP&E | 36.1m |
Other Non-Current Assets | 8.1m |
Current Liabilities | 83.4m |
Accounts Payable | 19.5m |
Accrued Liabilities | 34.7m |
Other Current Liabilities | 29.3m |
Non-Current Liabilities | 21.4m |
Other Non-Current Liabilities | 21.4m |
Earnings Waterfall
Deciphera Pharmaceuticals Inc
Revenue
|
174.9m
USD
|
Cost of Revenue
|
-5.3m
USD
|
Gross Profit
|
169.6m
USD
|
Operating Expenses
|
-376.1m
USD
|
Operating Income
|
-206.5m
USD
|
Other Expenses
|
16.1m
USD
|
Net Income
|
-190.4m
USD
|
Free Cash Flow Analysis
Deciphera Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
In 2023, QINLOCK's U.S. net product revenue reached $121.5 million, reflecting a 25% rise with solid demand. The Q4 revenue surged by 38% from the previous year's Q4 to $35.3 million. Anticipated continued growth in 2024 is underpinned by QINLOCK's standard of care status in fourth-line GIST, with gross to net estimates and Patient Assistance Program use remaining consistent. Internationally, QINLOCK gained traction, especially in Europe with a 56% Q4 revenue jump and expansion plans unfolding across Central and Eastern Europe, priming the international revenue for further growth. The U.S. market for TGCT is valued around $700 million, with Deciphera well-placed to grasp this opportunity. To broaden its therapeutic horizon, a Phase II study on vimseltinib for GVHD is set to start by year's end.
What is Earnings Call?
D05 Profitability Score
Profitability Due Diligence
Deciphera Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Deciphera Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
D05 Solvency Score
Solvency Due Diligence
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Deciphera Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
D05 Price Targets Summary
Deciphera Pharmaceuticals Inc
Dividends
Current shareholder yield for D05 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The company is headquartered in Waltham, Massachusetts and currently employs 280 full-time employees. The company went IPO on 2017-09-28. The firm has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The firm's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The company has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.
Contact
IPO
Employees
Officers
The intrinsic value of one D05 stock under the Base Case scenario is 13.51 EUR.
Compared to the current market price of 42.4 EUR, Deciphera Pharmaceuticals Inc is Overvalued by 68%.